



Research In China

The Vertical Portal for China Business Intelligence

STUDY GOAL AND OBJECTIVES

This report provides the industry executives with strategically significant competitor information, analysis, insight and projection on the competitive pattern and key companies in the industry, crucial to the development and implementation of effective business, marketing and R&D programs.

REPORT OBJECTIVES

- To establish a comprehensive, factual, annually updated and costeffective information base on market size, competition patterns, market segments, goals and strategies of the leading players in the market, reviews and forecasts.
- To assist potential market entrants in evaluating prospective acquisition and joint venture candidates.
- To complement the organizations' internal competitor information gathering efforts with strategic analysis, data interpretation and insight.
- ◆ To suggest for concerned investors in line with the current development of this industry as well as the development tendency.
- ◆ To help company to succeed in a competitive market, and

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. Initially, a comprehensive and exhaustive search of the literature on this industry was conducted. These sources included related books and journals, trade literature, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. Subsequently, telephone interviews or email correspondence was conducted with marketing executives etc. Other sources included related magazines, academics, and consulting companies.

INFORMATION SOURCES

The primary information sources include Company Reports, and National Bureau of Statistics of China etc.

Copyright 2012 ResearchInChina

ResearchInChina

The Vertical Portal for China Business Intelligence

Abstract

Pharmaceutical excipients refer to adjuvants and additives used for production of pharmaceuticals and compounding of prescriptions. In addition to active ingredients, pharmaceutical excipients are also contained in pharmaceutical preparations after reasonable safety assessment.

China has launched more than 500 types of pharmaceutical excipients, far less than 1,500 types of the United States and 3,000 types of Europe. By market size, gelatin capsules, sucrose, starch, film-coated powder, 1,2-propylene glycol, polyvinylpyrrolidone (PVP), hydroxypropyl methyl cellulose (HPMC), microcrystalline cellulose, hydroxypropyl cellulose (HPC) and lactose rank as the top 10 pharmaceutical excipients in China.

Among them, the traditional pharmaceutical excipients --gelatin capsules are involved with adequate supply and large export volume. In H1 2014, China's gelatin capsule export volume amounted to 1,427.5 tons and the export value hit USD32.408 million. However, China still relies on the import of film-coated powder, polyvinylpyrrolidone (PVP) and other new-type high-end pharmaceutical excipients.

Capacity and Number of Pharmaceutical Excipients Species of Major Pharmaceutical Excipients Enterprises in China, 2014



Source: China Pharmaceutical Excipients Industry Report, 2014-2017 by ResearchInChina

Research In China

The Vertical Portal for China Business Intelligence

Currently, pharmaceutical excipients account for about 2%-3% of China's total output value of pharmaceutical preparations. Chinese pharmaceutical excipient market size reached about RMB26.35 billion in 2013 and is expected to be RMB54.83 billion in 2017.

There are about 400 pharmaceutical excipient manufacturers in China, of which over 90 ones or 23% specialize in the production of pharmaceutical excipients, while most of the remaining ones focus on chemical or food processing.

Currently, foreign leading pharmaceutical excipient companies, such as Colorcon (the USA), Degussa (Germany), Meggle (Germany) and Roquette (France), have set up joint ventures, wholly-owned companies or offices in China. Colorcon mainly provides film-coated products; Meggle pharmaceutical lactose, and Roquette pharmaceutical starch and polyols.

Chinese pharmaceutical excipient giants include Er-Kang Pharmaceutical, Sunhere Pharmaceutical Excipients, Dongbao Bio-Tech, Qinghai Gelatin, Shandong Liaocheng A Hua Pharmaceutical, Zhanwang Pharmaceutical and Qufu Tianli, but their market concentration rate is rather low. As a tycoon, Er-Kang Pharmaceutical only seized about 2.7% market share in 2013.

Ranking among the largest Chinese pharmaceutical excipient producers with the most complete types, Er-Kang Pharmaceutical holds 116 types of pharmaceutical excipients and the capacity of 45,000 tons or more. Over the past two years, the company has continued to enforce epitaxial expansion strategy and accelerate market layout. In March 2014, the company acquired 100% stake in Changsha Zhengyang Pharmaceutical Capsule and 51% stake in Hunan Dongting Citric Acid Chemicals. In addition, the company's 180,000 tons/a medicinal cassava starch production project went into operation on March 31, 2014; the first phase of "South China Pharmaceutical Excipient Base Construction Project" has been completed and will realize production goal at the end of 2014.

Sunhere Pharmaceutical Excipients is a Chinese member of International Pharmaceutical Excipient Confederation (IPEC), mainly producing microcrystalline cellulose, hydroxypropyl cellulose, hypromellose and other 18 types of new-type pharmaceutical excipients with the capacity of 10,000 tons. On April 24, 2014, Sunhere Pharmaceutical Excipients planned to go public so as to raise funds for 7,100 tons/a new-type pharmaceutical excipient production line expansion project.

Copyright 2012ResearchInChina

Research In China

The Vertical Portal for China Business Intelligence

Zhanwang Pharmaceutical produces 28 types of pharmaceutical excipient products including carboxymethyl starch sodium, pre-gelatinized starch, hypromellose, microcrystalline cellulose, etc., with the capacity of over 10,000 tons. Some production bases of the company have passed the certification of the US FDA and the European COS. Now, export has contributed 25% to the company's revenue.

The report includes the following aspects:

- Departing environment (including economy, policies, barriers to entry, upstream and downstream environment) of China pharmaceutical excipient industry;
- Status quo, competition pattern, import & export and development trend of China pharmaceutical excipient industry;
- Department of the property of 10 major Chinese pharmaceutical excipient companies;
- Development forecast and operation comparison between major enterprises in China pharmaceutical excipient industry.

Table of contents

1 Overview of Pharmaceutical Excipients

- 1.1 Overview
- 1.2 Classification

2 Operating Environment of China **Pharmaceutical Excipient Industry**

- 2.1 Economy
- 2.2 Policies
- 2.3 Entry Barriers
- 2.3.1 Qualification
- 2.3.2 R & D and Technology
- 2.3.3 Marketing Channels and Brands
- 2.3.4 Funds
- 2.4 Upstream and Downstream Environment
- 2.4.1 Upstream
- 2.4.2 Downstream

3 Development of China Pharmaceutical **Excipient Industry**

- 3.1 International Market
- 3.2 Status Quo
- 3.3 Competition Pattern
- 3.4 Import and Export
- 3.4.1 Import
- 3.4.2 Export
- 3.5 Breakdown Products
- 3.5.1 Pharmaceutical Gelatin
- 3.5.2 Hydroxypropyl Methyl Cellulose (HPMC)

- 3.5.3 Pharmaceutical Starch
- 3.5.4 Pharmaceutical Sucrose
- 3.5.5 Propanediol
- 3.6 Development Trend
- 3.6.1 Marketing Channels and Brand Building Are 4.2.3 Revenue Structure Strengthened
- 3.6.2 The Industry Heads toward Production Specialization and Standardization
- 3.6.3 The Varieties of Pharmaceutical Excipients Increase
- 3.6.4 Downstream Pharmaceutical Preparation **Industry Boosts Pharmaceutical Excipient** Industry
- 3.6.5 Industrial Concentration Rate Will Ascend Gradually
- 3.6.6 Technological Development Turns the Focus 4.7 Zhanwang Pharmaceutical to Security, Functionality, Adaptability, Efficiency, etc.
- 3.6.7 Composite Excipients Will Be One **Development Direction of Pharmaceutical Excipients**

4 Major Companies

- 4.1 Er-Kang Pharmaceutical
- 4.1.1 Profile
- 4.1.2 Operation
- 4.1.3 Revenue Structure
- 4.1.4 Gross Margin
- 4.1.5 R & D and Investment
- 4.1.6 Pharmaceutical Excipient Business

- 4.1.7 Forecast and Outlook
- 4.2 Sunhere Pharmaceutical Excipients
- 4.2.1 Profile
- 4.2.2 Operation
- 4.2.4 Gross Margin
- 4.2.5 R & D and Investment
- 4.2.6 Output and Sales Volume
- 4.2.7 Supply
- 4.2.8 Forecast and Outlook
- 4.3 Dongbao Bio-Tech
- 4.4 Qinghai Gelatin
- 4.5 Shandong Head
- 4.6 Shandong Liaocheng A Hua Pharmaceutical
- 4.8 Qufu Tianli
- 4.9 North China Pharmaceutical
- 4.10 Joinway Pharmaceutical

5 Forecast and Outlook

- 5.1 Industrial Development Forecast
- 5.2 Operation Comparison between Major Enterprises
- 5.2.1 Revenue
- 5.2.2 Net Profit
- 5.2.3 Net Profit Margin
- 5.2.4 Gross Margin
- 5.2.5 Pharmaceutical Excipient Business

- Classification of Pharmaceutical Excipients
- China's GDP and YoY Growth Rate, 1985-2014
- Policies and Regulations on China Pharmaceutical Excipient Industry
- China's Corn Starch Output, 2009-2013
- China's Corn Starch Price, Oct-Nov 2014
- China's Refined Cotton Price, Dec 2013-Apr 2014
- China's Chemical Preparation Manufacturing Revenue and YoY Growth, 2009-2013
- China's Chinese Patent Medicine Manufacturing Revenue and YoY Growth, 2009-2013
- China's Biological and Biochemical Manufacturing Revenue and YoY Growth, 2009-2013
- China's Pharmaceutical Excipient Market Size, 2009-2014
- Structure of Chinese Pharmaceutical Excipient Enterprises (by Type)
- Market Share of Major Chinese Pharmaceutical Excipient Companies, 2013
- Products, Categories and Capacity of Major Chinese Pharmaceutical Excipient Companies, 2013
- Top 10 Gelatin Capsule Import Sources of China by Import Volume and Value, 2013-2014
- Top 10 Gelatin Capsule Export Destinations of China by Export Volume and Value, 2013-2014
- Gelatin Consumption Structure (%) by Country / Region
- China's Gelatin Output Structure (by Type)
- China's Gelatin and Bone Gelatin Market Capacity, 2005-2014
- China's MC/HPMC Capacity, 2006-2013
- China's Pharmaceutical Cellulose Ether Demand, 2009-2016E
- China's Starch Output, 2009-2013
- Proportion of China's Starch Output (by Product)
- China's Starch Import and Export (by Product), 2013
- China's Medicinal Starch Quality Index
- China's Medicinal Starch Demand, 2011-2015E

- China's Sugar Output and YoY Growth Rate, 2006/07-2013/14
- Output Proportion of China's Main Sugar Producing Areas, 2013-2014
- Quality Index Comparison between Medicinal Sucrose and White Sugar
- China's Propanediol Output and YoY Growth, 2005-2010
- China's Propanediol Import and Export, Jan-Sep 2014
- Revenue and Net Income of Er-Kang Pharmaceutical, 2009-2014
- Revenue of Er-Kang Pharmaceutical (by Product), 2009-2014
- Revenue Structure of Er-Kang Pharmaceutical (by Product), 2009-2014
- Revenue of Er-Kang Pharmaceutical (by Region), 2009-2014
- Revenue Structure of Er-Kang Pharmaceutical (by Region), 2009-2014
- Gross Margin of Er-Kang Pharmaceutical, 2009-2014
- Gross Margin of Er-Kang Pharmaceutical (by Product), 2009-2014
- R & D Costs and % of Total Revenue of Er-Kang Pharmaceutical, 2009-2013
- Completion of Fund-raising Projects of Er-Kang Pharmaceutical, 2013
- Pharmaceutical Excipient Revenue and % of Total Revenue of Er-Kang Pharmaceutical, 2009-2014
- Main Pharmaceutical Excipient Capacity of Er-Kang Pharmaceutical, 2013
- Revenue and Net Income of Er-Kang Pharmaceutical, 2012-2017E
- Revenue and Net Income of Sunhere Pharmaceutical Excipients, 2011-2013
- Revenue of Sunhere Pharmaceutical Excipients (by Product), 2011-2013
- Revenue Structure of Sunhere Pharmaceutical Excipients (by Product), 2011-2013
- Revenue of Sunhere Pharmaceutical Excipients (by Region), 2011-2013
- Revenue Structure of Sunhere Pharmaceutical Excipients (by Region), 2011-2013
- Gross Margin of Sunhere Pharmaceutical Excipients, 2011-2013
- R & D Costs and % of Total Revenue of Sunhere Pharmaceutical Excipients, 2011-2013
- Fund-raising Projects of Sunhere Pharmaceutical Excipients and Allocation of Raised Funds

- Capacity, Capacity Utilization and Sales-Output Ratio of Main Products of Sunhere Pharmaceutical Excipients, 2011-2013
- Top Five Customers of Sunhere Pharmaceutical Excipients in Basic Raw Material Products, 2011-2013
- Top Five Customers of Sunhere Pharmaceutical Excipients in Crude-product Fine Processing Products, 2011-2013
- Top Five Suppliers of Sunhere Pharmaceutical Excipients in Basic Raw Material Production, 2011-2013
- Top Five Suppliers of Sunhere Pharmaceutical Excipients in Excellent-product Fine Processing and Production, 2011-2013
- Revenue and Net Income of Sunhere Pharmaceutical Excipients, 2012-2017E
- Revenue and Net Income of Dongbao Bio-Tech, 2010-2014
- Revenue of Dongbao Bio-Tech (by Product), 2010-2014
- Revenue of Dongbao Bio-Tech (by Region), 2011-2014
- Revenue Structure of Dongbao Bio-Tech (by Region), 2011-2014
- Gross Margin of Dongbao Bio-Tech, 2011-2014
- Gross Margin of Dongbao Bio-Tech (by Product), 2011-2014
- Gross Margin of Dongbao Bio-Tech (by Region), 2011-2013
- R & D Costs and % of Total Revenue of Dongbao Bio-Tech, 2011-2013
- Completion of Fund-raising Projects of Dongbao Bio-Tech, 2013
- Pharmaceutical Gelatin Revenue of Dongbao Bio-Tech, 2010-H1 2014
- Revenue and Net Income of Dongbao Bio-Tech, 2012-2017E
- Revenue and Net Income of Qinghai Gelatin, 2010-2014
- Revenue of Qinghai Gelatin (by Product), 2010-2014
- Revenue of Qinghai Gelatin (by Sector), 2010-2014
- Revenue of Qinghai Gelatin (by Region), 2011-2014
- Revenue Structure of Qinghai Gelatin (by Region), 2011-2014
- Gross Margin of Qinghai Gelatin, 2010-2014
- Gross Margin of Qinghai Gelatin (by Product), 2010-2014
- Gross Margin of Qinghai Gelatin (by Region), 2012-2014

- Pharmaceutical Excipient Revenue and% of Total Revenue of Qinghai Gelatin, 2010-2014
- Revenue and Net Income of Qinghai Gelatin, 2012-2017E
- Classification and Properties of Cellulose Ether
- Revenue and Net Income of Shandong Head, 2011-2013
- Revenue of Shandong Head (by Product), 2011-2013
- Revenue Structure of Shandong Head (by Product), 2011-2013
- Revenue of Shandong Head (by Region), 2011-2013
- Revenue Structure of Shandong Head (by Region), 2011-2013
- Domestic Revenue of Shandong Head (by Region), 2011-2013
- Overseas Revenue of Shandong Head (by Region), 2011-2013
- Gross Margin of Shandong Head, 2011-2013
- Gross Margin of Shandong Head (by Product), 2011-2013
- R & D Costs and % of Total Revenue of Shandong Head, 2011-2013
- Fund-raising Projects of Shandong Head and Allocation of Raised Funds
- Pharmaceutical Excipient Revenue, % of Total Revenue and Gross Margin of Shandong Head, 2011-2013
- Capacity, Output and Sales Volume of Main Products of Shandong Head, 2011-2013
- Diacetone Acrylamide Capacity, Output and Sales Volume of Shandong Head, 2011-2013
- Top Five Customers of Shandong Head, 2011-2013
- Top Five Suppliers of Shandong Head, 2011-2013
- Revenue and Net Income of Shandong Head, 2012-2017E
- Total Assets, Revenue and Net Income of Shandong Liaocheng A Hua Pharmaceutical, 2010-2014
- Capacity and Application of Main Products of Shandong Liaocheng A Hua Pharmaceutical
- Revenue of Zhanwang Pharmaceutical, 2012-2016E
- Capacity of Main Pharmaceutical Excipient Products of Qufu Tianli
- Revenue and Net Income of North China Pharmaceutical, 2009-2014



- Revenue of North China Pharmaceutical (by Product), 2009-2014
- Revenue Structure of North China Pharmaceutical (by Product), 2009-2014
- Revenue of North China Pharmaceutical (by Region), 2009-2014
- Revenue Structure of North China Pharmaceutical (by Region), 2009-2014
- Chinese Pharmaceutical Excipient Market Size, 2012-2017E
- Revenue of Major Companies in China Pharmaceutical Excipient Industry, 2009-2013
- Net Income of Major Companies in China Pharmaceutical Excipient Industry, 2009-2013
- Net Profit Margin of Major Companies in China Pharmaceutical Excipient Industry, 2009-2013
- Gross Margin of Major Companies in China Pharmaceutical Excipient Industry, 2009-2013
- Pharmaceutical Excipient Revenue of Major Chinese Pharmaceutical Excipient Companies, 2009-2013

Research nChina

The Vertical Portal for China Business Intelligence

How to Buy

You can place your order in the following alternative ways:

- 1.Order online at www.researchinchina.com
- 2.Fax order sheet to us at fax number:+86 10 82601570
- 3. Email your order to: report@researchinchina.com
- 4. Phone us at +86 10 82600828/ 82601561

Party A:		
Name:		
Address:		
Contact Person:	Tel	
E-mail:	Fax	

Party B:					
Name:	Beijing Waterwood Technologies Co., Ltd (ResearchInChina)				
Address:	Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080				
Contact Person:	Liao Yan	Phone:	86-10-82600828		
E-mail:	report@researchinchina.com	Fax:	86-10-82601570		
Bank details:	Beneficial Name: Beijing Waterwood Technologies Co., Ltd Bank Name: Bank of Communications, Beijing Branch Bank Address: NO.1 jinxiyuan shijicheng,Landianchang,Haidian District,Beijing Bank Account No #: 110060668012015061217 Routing No #: 332906 Bank SWIFT Code: COMMCNSHBJG				

Title	Format	Cost
Total		

Choose type of format

PDF (Single user license)2,30	00 USD
Hard copy2,56	00 USD
PDF (Enterprisewide license) 3,60	00 USD

※ Reports will be dispatched immediately once full payment has been received.
Payment may be made by wire transfer or credit card via PayPal.





RICDB service

About ResearchInChina

ResearchInChina (www.researchinchina.com) is a leading independent provider of China business intelligence. Our research is designed to meet the diverse planning and information needs of businesses, institutions, and professional investors worldwide. Our services are used in a variety of ways, including strategic planning, product and sales forecasting, risk and sensitivity management, and as investment research.

Our Major Activities

- □ Multi-users market reports
- □ Database-RICDB
- □ Custom Research
- □ Company Search

RICDB (http://www.researchinchina.com/data/database.html), is a visible financial data base presented by map and graph covering global and China macroeconomic data, industry data, and company data. It has included nearly 500,000 indices (based on time series), and is continuing to update and increase. The most significant feature of this base is that the vast majority of indices (about 400,000) can be displayed in map.

After purchase of our report, you will be automatically granted to enjoy 2 weeks trial service of RICDB for free.

After trial, you can decide to become our formal member or not. We will try our best to meet your demand. For more information, please find at www.researchinchina.com

For any problems, please contact our service team at: